Group 1 - Mirxes Holding Limited, a leading cancer early screening company in Singapore, was listed on the Hong Kong Stock Exchange on May 23, 2025, and was included in the Hang Seng Composite Index and Hong Kong Stock Connect within four months, indicating strong international market recognition [1] - For the first half of 2025, Mirxes reported revenue of $10.5 million, a 9.4% increase compared to the same period in 2024, with gross profit reaching $7.1 million, up 51.1%, and gross margin significantly improving from 49.0% to 67.6% [1] - The company's loss decreased by 36.3% year-on-year to $28.23 million, reflecting improved financial performance [1] Group 2 - Mirxes was founded in 2014 and is a global leader in RNA liquid biopsy, focusing on the research of blood cfRNA and cfDNA, while integrating information from proteins, imaging, and epidemiology through multi-dimensional machine learning models [1] - The company has developed its proprietary mSMRT-qPCR technology platform and has conducted multiple studies in early screening for gastric, lung, and breast cancers, with research published in international journals such as Gut, PNAS, and Cancers [1] - In 2020, Mirxes initiated the first national standard for microRNA diagnostics in Singapore, collaborating with prestigious institutions, and is set to be included in the ISO certification system [2] - The company launched the world's first serum gastric cancer molecular diagnostic kit, GASTRO ClearTM, in Singapore in 2019 and was recognized by Nature Biotechnology as the only Asian company on the "Global Liquid Biopsy Innovation Companies" list [2]